Celleration, Inc., a privately held medical device company focused on developing and commercializing therapeutic ultrasound healing technologies to treat wounds, has announced they received FDA clearance for their next generation UltraMIST System.
The UltraMIST System is Celleration's latest addition to its line of MIST Therapy products. MIST Therapy is low-frequency ultrasound delivered through a saline mist to accelerate wound healing. Unlike conventional wound treatments that are limited to treating the surface, MIST Therapy delivers ultrasound energy into and below the wound bed to stimulate cells and shorten the healing process.
"The UltraMIST System incorporates today's state of the art technology into a smaller, sleeker, user-friendly design," stated Mark Wagner, President and CEO of Celleration, Inc. "UltraMIST was developed as a platform technology to meet the needs of our customers and to allow for rapid and efficient future product expansions. Celleration's investment in new product development, high-quality clinical studies, and exceptional customer service demonstrate our continued commitment to providing solutions for the growing wounded patient population."
In the US alone, up to $25 billion is spent each year to treat chronic, non-healing wounds. With the aging population, longer life expectancies, and increasing number of coexisting illnesses such as diabetes, heart failure, obesity, pulmonary and vascular diseases, and more, this number is only expected to grow. Providing technologies that reduce the time to heal yet are easy for healthcare providers to use are necessary to reduce these expenditures and improve patient quality of care. MIST Therapy has been used over 1.2 million times to benefit over 80,000 patients.